Glioma is a malignant tumor with the highest incidence among all brain tumors (about 46% of intracranial tumors) and is the most common primary intracranial tumor. Among them, glioblastoma (GBM) is highly malignant and is one of the three refractory tumors with the highest mortality rate in the world. The survival time from glioblastoma diagnosis to death is only 14–16 months for patients with standard treatment such as surgery plus radiotherapy and chemotherapy. Due to its high malignancy and poor prognosis, in-depth studies have been conducted to explore effective therapeutic strategies for glioblastoma. In addition to the conventional surgery, radiotherapy, and chemotherapy, the glioblastoma treatments also include targeted therapy, immunotherapy, and electric field treatment. However, current treatment methods provide limited benefits because of the heterogeneity of glioblastoma and the complexity of the immune microenvironment within a tumor. Therefore, seeking an effective treatment plan is imperative. In particular, developing an active immunotherapy for glioblastoma has become an essential objective in the field. This article reviews the feasibility of CD47/CD24 antibody treatment, either individually or in combination, to target the tumor stem cells and the antitumor immunity in glioblastoma. The potential mechanisms underlying the antitumor effects of CD47/CD24 antibodies are also discussed.

中文翻译：

---

靶向CD47或CD24的抗体治疗胶质母细胞瘤的前景

胶质瘤是所有脑肿瘤中发病率最高的恶性肿瘤（约占颅内肿瘤的46%），是最常见的原发性颅内肿瘤。其中，胶质母细胞瘤（GBM）恶性程度高，是全球死亡率最高的三大难治性肿瘤之一。对于手术加放化疗等标准治疗的患者，从胶质母细胞瘤诊断到死亡的生存时间仅为14-16个月。由于其恶性程度高和预后差，已进行深入研究以探索胶质母细胞瘤的有效治疗策略。胶质母细胞瘤的治疗除常规手术、放疗、化疗外，还包括靶向治疗、免疫治疗、电场治疗等。然而，由于胶质母细胞瘤的异质性和肿瘤内免疫微环境的复杂性，目前的治疗方法提供的益处有限。因此，寻求有效的治疗方案势在必行。特别是，开发针对胶质母细胞瘤的主动免疫疗法已成为该领域的重要目标。本文回顾了 CD47/CD24 抗体单独或联合治疗靶向肿瘤干细胞和胶质母细胞瘤抗肿瘤免疫的可行性。还讨论了 CD47/CD24 抗体抗肿瘤作用的潜在机制。开发针对胶质母细胞瘤的主动免疫疗法已成为该领域的重要目标。本文回顾了 CD47/CD24 抗体单独或联合治疗靶向肿瘤干细胞和胶质母细胞瘤抗肿瘤免疫的可行性。还讨论了 CD47/CD24 抗体抗肿瘤作用的潜在机制。开发针对胶质母细胞瘤的主动免疫疗法已成为该领域的重要目标。本文回顾了 CD47/CD24 抗体单独或联合治疗靶向肿瘤干细胞和胶质母细胞瘤抗肿瘤免疫的可行性。还讨论了 CD47/CD24 抗体抗肿瘤作用的潜在机制。